mild cognitive impairment Cytox Gets CE Mark for Alzheimer's Disease Genetic Risk Test The polygenic risk test analyzes an individual's genes for more than 100,000 SNPs associated with the risk of developing Alzheimer's disease. DiamiR Wins $3.9M in NIH Funding for Neurological Disease Diagnostic Development The two grants awarded will support DiamiR's development of microRNA diagnostics for mild cognitive impairment, Alzheimer's disease, and Rett syndrome. Alzheimer's Disease Neuroimaging Initiative Enters Third Phase The initiative was launched to conduct a large-scale study of cognitive impairment and Alzheimer's disease to advance the discovery of biomarkers of the conditions. Affymetrix, Cytox Partner on Alzheimer's Disease Risk Dx The partners will collaborate on the development of a custom SNP panel to predict an individual's Alzheimer's disease or MCI risk. Estonian Population Profiling Reveals Recurrent, Rare CNVs Linked to Intellectual Ability More than 10 percent of individuals in an unselected population carried recurrent syndrome-associated CNVs or rare autosomal CNVs with potential ties to cognitive ability. Mar 16, 2015 Diamir Receives $1.5M NIH Grant to Advance microRNA Dx for Alzheimer's Nov 21, 2014 New Blood-based Alzheimer's Biomarker Panel Uses Exosomal miRNA Premium Jul 14, 2014 C2N, WUSTL Expand Partnership to Commercialize Alzheimer's Test Nov 4, 2013 Genomind, Emory Partner to Commercialize Alzheimer's Test Jun 6, 2013 DiaGenic Adopts Life Tech QuantStudio Dx for Alzheimer's Test Development Premium Mar 29, 2012 DiaGenic-GE Pact Aims for MDx Test to ID Alzheimer's Risk Patients for Follow-up PET Imaging Premium Mar 22, 2012 NINR Seeks Biomarker, Imaging Studies of Mild Cognitive Impairment Nov 4, 2011 Myriad Moving Eight Protein-Based Tests to Market; Priorities Include AD, Kidney Damage, Colon Cancer Premium Dec 10, 2010 Initial Analysis of ADNI Plasma Proteome Data Suggests Possible Protein Signatures for Alzheimer's Premium Oct 7, 2010 Norwegian MDx Firm DiaGenic Raises $12.1M While Refocusing Business on Neuro Market Premium Sep 17, 2010 TARC Team Uses RBM's DiscoveryMAP Platform to Develop Alzheimer's Protein-Biomarker Test Premium Jun 11, 2010 ADNI Researchers and Industry Partners Developing Proteomic Profiles to Track Alzheimer's Disease Premium Breaking News SARS-CoV-2 Mutational Signature Associated With Mutagenic Antiviral Drug Biocartis Restructures Balance Sheet as H1 2023 Revenues Rise 12 Percent Rare Kidney Cancer Genomic Analysis Reveals Potential Target, Suggests Treatment SEC Concludes CareDx Investigation, Recommends No Enforcement Action Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.